% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Klein:294449,
      author       = {E.-M. Klein and S. Hujic and K. Miah and A. Benner$^*$ and
                      M. Merz and U. Bertsch and N. Weinhold and H. Goldschmidt
                      and S. Sauer},
      title        = {{E}fficacy and {S}afety of {A}utologous {S}tem {C}ell
                      {T}ransplantation in {F}irst-{L}ine {T}reatment and at
                      {R}elapse in {E}lderly {P}atients with {M}ultiple
                      {M}yeloma.},
      journal      = {Oncology},
      volume       = {103},
      issn         = {0030-2414},
      address      = {Basel},
      publisher    = {Karger},
      reportid     = {DKFZ-2024-02274},
      pages        = {389–399},
      year         = {2025},
      note         = {Oncology 2025;103:389–399},
      abstract     = {Although recent data suggest that melphalan high-dose
                      therapy followed by autologous stem cell transplantation
                      (HDT/ASCT) is safe and effective in eligible multiple
                      myeloma (MM) patients up to the age of 75 years, its value
                      in elderly MM patients is still controversially discussed.We
                      retrospectively analyzed 607 MM patients ≥60 years old,
                      who were admitted to our institution for first-line or
                      salvage HDT/ASCT between January 2007 and October 2018. We
                      assigned them to three groups according to age at HDT/ASCT:
                      60-64 years (S1), 65-69 years (S2) and ≥70 years (S3). We
                      compared progression-free and overall survival, duration of
                      hospitalization, complications, transfers to intermediate or
                      intensive care unit, readmissions after discharge and deaths
                      within 100 days after HDT/ASCT between these groups.Age did
                      not impact progression-free and overall survival after
                      first-line and salvage HDT/ASCT. Patients ≥70 years old at
                      first HDT/ASCT had a longer hospitalization compared to
                      patients 60-64 years old; however, the difference in the
                      length of hospitalization was only marginal. Rates of
                      febrile neutropenia, mucositis, transfers to intermediate or
                      intensive care unit, readmissions after discharge, and
                      deaths within 100 days after HDT/ASCT were similar in the 3
                      age groups of patients receiving first or salvage HDT/ASCT.
                      Patients with a Charlson Comorbidity Index ≥2 receiving
                      first HDT/ASCT had a higher risk for a transfer to
                      intermediate or intensive care unit.Our analysis shows that
                      HDT/ASCT is safe and effective in eligible elderly MM
                      patients in first-line treatment and at relapse. A careful
                      patient selection according to biological rather than
                      chronological age is of crucial importance.},
      keywords     = {Autologous stem cell transplantation (Other) / Elderly
                      patients (Other) / Multiple myeloma (Other) / Survival
                      (Other) / Toxicity (Other)},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39362191},
      doi          = {10.1159/000541541},
      url          = {https://inrepo02.dkfz.de/record/294449},
}